The control of feeding behaviour by GLP-1 and exendin-4 has been explored in Zucker obese rats, resulting in a reduction in food intake, with exendin-4 being much more potent than GLP-1
Of these, 20 were assigned to receive 5 mcg of subcutaneous exenatide twice daily for 1 month, followed by 10 mcg twice daily for 11 months, while 24 were placed in the control group
Since the late 1990s, several pharmacological agents have received regulatory approval for chronic weight management in both Europe and the United States
And it means that when a stall does occur on GLP-1 therapy, the appetite component is playing a smaller role than it would on a diet, which tells you to look at other factors first
POMC is processed into alpha- melanocyte-stimulating hormone (-MSH) , which binds to melanocortin receptors and exerts anorexigenic effects